 

Term

Description

 

Group Company

Our group company, namely Hinshitsu Manufacturing Private Limited as described in “Our Group
Companies” on page 207

 

Independent Directors

Independent directors on our Board

 

Individual Promoter

Gangadi Madhukar Reddy

 

“Investor Selling Shareholder” or
“PIOF” or “Premji Invest”

PI Opportunities Fund - I

 

IPO Committee

The IPO committee of our Board, as described in “Our Management” on page 196

 

KMPL.

Kalyani Meditimes Private Limited

 

“Key Managerial Personnel” or
“KNP”

Key managerial personnel of our Company in accordance with Regulation 2(1)(bb) of the SEBI ICDR
Regulations including key managerial personnel under Section 2(51) of the Companies Act as described
in “Our Management” on page 200

 

Lavender Rose

Lavender Rose Investment Ltd, belonging to the Warburg Pincus group

 

Lone Furrow

Lone Furrow Investments Private Limited

 

Madhukar
Agreement

Employment

‘Our Company and our Managing Director and Chief Executive Officer, Gangadi Madhukar Reddy have
entered into an employment agreement dated April 5, 2019, setting out the terms of his employment as
amended pursuant to amendment agreement dated February 5, 2021

 

Managing Director and Chief
Executive Officer

Managing director and Chief Executive Officer of our Company, Gangadi Madhukar Reddy

 

Material Subsidiary

Subsidiaries which contribute 10% or more to the turnover or net-worth or profits before tax of the
immediately preceding financial year included in the Restated Financial Statements. Accordingly,
Optival Health Solutions Private Limited is the Material Subsidiary of our Company

 

MHSPPL

MHS Pharmaceuticals Private Limited

 

“Memorandum of Association” or
“MoA”

Memorandum of association of our Company, as amended

 

 

NSPPL Nova Sud Pharmaceuticals Private Limited
Nomination and Remuneration] The nomination and remuneration committee of our Board, constituted in accordance with the
Committee applicable provisions of the Companies Act, 2013 and the Listing Regulations and as described in “Our

Management” on page 194

 

Non-Executive Director

Non-Executive director on our Board

 

Optival

Optival Health Solutions Private Limited

 

Other Selling Shareholders

Collectively, S. S. Pharma LLC, Natco Pharma Limited, Time Cap Pharma Labs Private Limited, Shore
Pharma LLC, A. Raghava Reddy, K Prakurthi, Navdeep Patyal, Sangeeta Raju, R. Venkat Reddy, TK
Kurien, Nithya Venkataramani, Atul Gupta, Manoj Jaiswal, Rahul Garg, Kollengode Ramanathan
Lakshminarayana and Bijou Kurien

 

 

Preference Shares

Collectively, the following preference shares, (i) 2,836,421 Series A CCP, (ii) 8,956,480 Series B
CCPS, (iii) 1,721,445 Series B1 CPS, (iv) 1,676,418 Series B2 CCPS, (v) 560,896 Series C1 CCPS,
and (vi) 160,147 Series C2 CCPS

 

Promoters

Collectively, the Individual Promoter and the Corporate Promoters

 

Promoter Group

Individuals and entities constituting the promoter group of our Company in terms of Regulation 2(1)(pp)
of the SEBI ICDR Regulations, as described in “Our Promoters and Promoter Group” on page 206

 

Settlement Letter

Settlement letter dated November 27, 2021 issued by G. Madhukar Reddy, Lone Furrow Investments
Private Limited, Agilemed Investments Private Limited, Gangadi Investments Private Limited to PI
Opportunities Fund — 1

 

Registered Office

The registered office of our Company situated at 707, 7th Floor, 5-9-13, Taramandal Commercial
Complex, Saifabad, Hyderabad 500 004, Telangana, India

 

“Registrar oF

“RoC”

of Companies™

Registrar of Companies, Telangana at Hyderabad

 

Restated Consolidated Financial
Information

The restated consolidated financial information of our Company, along with our Subsidiaries,
comprising of the restated consolidated balance sheet as at September 30, 2021, September 30, 2020,
March 31, 2021, March 31, 2020 and March 31, 2019, and the restated consolidated statement of profit
and loss (including other comprehensive income), and restated consolidated statement of cash flows and
restated consolidated statement of changes in equity for the six months ended September 30, 2021 and
September 30, 2020 and for the financial years ended March 31, 2021, March 31, 2020 and March 31,
2019, together with its notes, annexures and schedules are derived from our audited consolidated
financial statements as at and for the six months ended September 30, 2021 and September 30, 2020
and for the financial years ended March 31, 2021, March 31, 2020 and March 31, 2019 prepared in
accordance with Ind AS, and restated in accordance with requirements of Section 26 of Part I of Chapter
III of Companies Act, SEBI ICDR Regulations and the Guidance Note on “Reports in Company
Prospectuses (Revised 2019)” issued by ICAI

 

 

Ritemed

 

Ritemed Pharma Retail Private Limited

 

 
